Influential cancer group to add drug-cost data to its treatment advice

When a U.S. cancer patient is prescribed drugs by their doctors now, the financial consequences play out over the course of treatment. But amid a growing national debate over drug prices, an influential coalition of cancer treatment centers, the National Comprehensive Cancer Network, will provide patients with info on the relative costs of different treatments, so they and their doctors can make more informed decisions. More from FiercePharma

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

COVID-19 vaccine makers' recent safety pledge continues to increase positive sentiment among Americans, new Harris Poll data say.

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.